PFE · 8-K · 20260804PR000094
Hospital Biosimilars Demand
PFIZER INC · 2026-08-04 · Importance 69 · Surprise 64 · From source text
Hospital and Biosimilars revenue was broadly stable worldwide at $1.640 billion in the second quarter, with U.S. growth of 7% offset by a 7% international decline. Oncology biosimilars revenue increased 2% worldwide and 14% internationally to $359 million. Inflectra revenue rose 23% worldwide and 66% in the U.S. to $171 million, while international Inflectra revenue fell 86% to $5 million. For the first six months, Hospital and Biosimilars revenue increased 6% worldwide and 19% in the U.S., led by oncology biosimilars growth of 24%.
Key facts
- Global Hospital and Biosimilars Division revenues for Six Months 2026: $2,403 million, up 13% (or 11% operational) versus 2025; U.S. $1,775 million up 19%; International $628 million down 2% source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +1.8% | Global Hospital and Biosimilars Division revenues for Six Months 2026: $2,403 million, up 13% (or 11% operational) versus 2025; U.S.… |